Alterity Therapeutics CEO to attend BTIG Biotechnology Conference 2026
David Stamler will hold one-on-one investor meetings during the virtual conference set for July 28-29, 2026.
Alterity Therapeutics announced on July 21, 2026 that Chief Executive Officer David Stamler, M.D., will participate in the BTIG Biotechnology Conference 2026, held virtually on July 28-29, 2026.1 At the event, Stamler will hold one-on-one meetings with investors in the United States.1
Alterity describes itself as a clinical stage biotechnology company focused on developing disease modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders.1 The company said it is preparing to initiate a Phase 3 pivotal trial in MSA, which it characterizes as a rare and rapidly progressive disease.1
Its lead compound, ATH434, was tested in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA patients, which the company said showed clinically meaningful efficacy.1 Alterity also said it has reported positive data from a separate open label Phase 2 trial in participants with advanced MSA.1
Beyond its clinical programs, Alterity said it maintains a broad drug discovery platform aimed at generating patentable compounds targeting the underlying pathology of neurological diseases.1 The company is headquartered in Melbourne, Australia, and San Francisco, California.1
The filing was submitted as a Form 6-K to the SEC and signed by Chairman Julian Babarczy on July 21, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.